Frederick Blume*
Managing Director
Excel Venture Management

Anthony Ratcliffe, PhD†
President and Chief Executive Officer
Synthasome, Inc

Todd Brady, MD, PhD
Senior Director of Business
Domain

Lesa Mitchell*
Vice President, Advancing Innovation
Ewing Marion Kauffman Foundation

Anthony Atala, MD*†
Director                                 
Wake Forest Institute for Regenerative Medicine

8:45–9:15 am

Introduction:

Keynote:

Advancements in Translational Medicine in the Military

Military support of translational medicine continues to lead the way for advancements in the field. What progress has the military made since the 2010 Translational Regenerative Medicine Forum and what can the industry look forward to from the military’s research and development?

Format: Keynote Address, Plenary

Colonel Janet R. Harris, RN, PhD
Director, Clinical and Rehabilitative Medicine Research Program
US Army Medical Research and Materiel Command

Lieutenant General Eric B. Schoomaker, MD, PhD
The Surgeon General and Commanding General
US Army Medical Command

Rocky S. Tuan, PhD†
Director, Center for Cellular and Molecular Engineering
University of Pittsburgh School of Medicine

Arnold I. Caplan, PhD†
Professor
Case Western Reserve University

Joachim Kohn, PhD†
Director
New Jersey Center for Biomaterials

George F. Muschler, MD†
Vice-Chairman of the Department of Biomedical Engineering
Vice Chairman of the Orthopaedic and Rheumatologic Institute
Lerner Research Institute

As healthcare is being reformed on a national level, this session will focus on a micro level to explore how the changes of healthcare will affect the field of regenerative medicine.
Format: Keynote Address

Richard A. Gephardt
President and Chief Executive Officer                                                                       

Gil Van Bokkelen, PhD*
Chairman and Chief Executive Officer
Athersys

Raymond H. Cypess, DVM, PhD†
Chairman, President and
Chief Executive Officer
ATCC

Vicki L. Seyfert-Margolis, PhD
Senior Advisor for Science
Innovation and Policy
US Food and Drug Administration

Lisa Beth Ferstenberg, MD
Director of Consulting Services Technical Resources International, Inc.

Celia M. Witten, PhD, MD
Director of the Office of 
Cellular, Tissue and Gene Therapy
US Food and Drug Administration

Regenerative medicine research and acquisitions are becoming a more common practice in big pharma. The science of regenerative medicine presents opportunities and barriers for new treatments and potential cures for diseases and ailments.

Format: Keynote Address, Plenary

Roy N. Davis
President                                                                                                                          
Johnson and Johnson Development Corporation

Commercialization Strategies and Challenges

To succeed with a regenerative medicine technology, biopharmaceuticals must adapt their strategies to overcome the new challenges that present when working to commercialize their product.

Jay Tong, MD
President and Chief Executive Officer
AllCells

Rosamund Smith, DPhil, Senior Research Advisor, Regenerative Biology, Biotechnology Discovery Research,
Eli Lilly

Roland DeAngelis
Senior Director, Global Advocacy
Genzyme

Chris Coburn
Executive Director
Cleveland Clinic Foundation
Innovations

David P. King*
Chairman and Chief Executive Officer
LabCorp

Steven Nichtberger, MD, President and Chief Executive Officer,
Tengion, Inc.

Commitment to Awareness/Supporting the Movement: “How Do We See Ourselves Collaboratively”

Atrium Ballroom

The mission of the Regenerative Medicine Foundation is to accelerate the discovery and development of new therapies for disease and translate those therapies into treatments for patients through the science of regenerative medicine. The field of regenerative medicine is not disease specific but in essence is a platform solution for a variety of different disease states.

Format: Panel

Margaret Anderson
Executive Director
FasterCures

Peter T. Lomedico, PhD
Strategic Alliances & Industry Partnerships
JDRF

Amy Miller, PhD
Public Policy Director
Personalized Medicine Coalition

Steven E. Wolf, MD
Betty and Bob Kelso Distinguished Chair in Burns and Trauma
Professor and Vice Chairman for Research, Dept. of Surgery
UT Health Science Center, San Antonio, Texas
Chief, Clinical Research
United States Army Institute of Surgical Research (USAISR)

Scott R. Burger, MD†
Principal
Advanced Cell & Gene Therapy, LLC

Harvard Apparatus

Deafness Research Foundation

HemaCare Corporation

University of Missouri and Organovo, Inc

Georgia Tech

Aastrom Bioscience

Question and Answer

Regenerative Medicine Coalition

Poster Session

Gala Dinner

Atrium Hall

Key Campaign Launch
Kelly Milukas
Contemporary Fine Art
Tiverton, Rhode Island

Caleb Winder
Co-founder and Director
Excel Venture Management

Michael F. Elliott
Partner
Noro-Moseley Partners

Steven Borst
Principal
Upstart Life Sciences Capital

Data requirements, supply chain issues, logistical challenges and associated costs that commercialization of regenerative medicine treatments

Format: Keynote Address, Plenary

Mahendra Rao, MD
Vice President, R & D
Primary and Stem Cell Systems
Invitrogen, part of Life Technologies

Terry Irgens, RPh, MS
Director
Armed Forces Institute of Regenerative Medicine

Ora Dar, PhD
Head of Life Sciences Sector
Israel Office of the Chief Scientist
Ministry of Industry Trade and Labor

The Regenerative Medicine Coalition is a new collaborative and capital efficient model for the translational medicine. Hear representatives from

• Berlin-Brandenburg Center for Regenerative Therapies (BCRT) at Charité
• Centre for Commercialization of Regenerative Medicine
• Centre for Stem Cell Research and Regenerative Medicine, University College London
• McGowan Institute for Regenerative Medicine
• National Center for Regenerative Medicine, Case Western Reserve (NCRM)
• Wake Forest Institute for Regenerative Medicine

Format: Panel

C. Randal Mills, PhD
President and Chief Executive Officer
Osiris Therapeutics, Inc.

Waleed Hassanien, MD
Chief Executive Officer
TransMedics, Inc

Scott Livingston
Chief Executive Officer
Livingston Securities, LLC

James H. Holmes IV, MD
Assistant Professor
Wake Forest Institute for Regenerative Medicine

Frank Hensley
Burn Survivor